Display options
Cite
Thaulow E, Guth BD, Ross J. Role of calcium channel blockers in experimental exercise-induced ischemia. Cardiovasc Drugs Ther. 1988;1(5):503-12doi: 10.1007/BF02125733.
Thaulow, E., Guth, B. D., & Ross, J. (1988). Role of calcium channel blockers in experimental exercise-induced ischemia. Cardiovascular drugs and therapy, 1(5), 503-12. https://doi.org/10.1007/BF02125733
Thaulow, E, et al. "Role of calcium channel blockers in experimental exercise-induced ischemia." Cardiovascular drugs and therapy vol. 1,5 (1988): 503-12. doi: https://doi.org/10.1007/BF02125733
Thaulow E, Guth BD, Ross J. Role of calcium channel blockers in experimental exercise-induced ischemia. Cardiovasc Drugs Ther. 1988 Jan;1(5):503-12. doi: 10.1007/BF02125733. PMID: 3154679.
Copy Download .nbib Format: NLM
Share it on

Cardiovasc Drugs Ther. 1988 Jan;1(5):503-12. doi: 10.1007/BF02125733.

Role of calcium channel blockers in experimental exercise-induced ischemia.

Cardiovascular drugs and therapy

E Thaulow, B D Guth, J Ross

Affiliations

  1. Seaweed Canyon Laboratory, La Jolla, California.

PMID: 3154679 DOI: 10.1007/BF02125733

Abstract

Calcium channel blockers, which induce vasodilation by relaxing vascular smooth muscle cells, have proven effective in the treatment of angina pectoris. To study mechanisms of calcium blockade in ischemic heart disease, conscious chronically instrumented dogs with a single coronary artery ameroid constrictor were studied during steady-state treadmill runs which induced regional myocardial ischemia. During exercise-induced ischemia, regional systolic wall thickening and subendocardial blood flow were both significantly reduced in the ischemic zone. Calcium channel blockade with verapamil, diltiazem, or nifedipine enhanced regional systolic wall thickening. Regional subendocardial blood flow in the ischemic region, measured during diltiazem and nifedipine experiments, improved during exercise. Reduced coronary artery resistance in the native vessels and/or recruitment of collaterals appears to largely explain the increased total myocardial blood supply in the jeopardized area and the increased function. However, after diltiazem, reduced exercise heart rates as well as reduced left ventricular end-diastolic pressure also contributed to the improvement in the oxygen-supply imbalance in the ischemic myocardium. These data provide a basis for understanding the efficacy of calcium channel blocker treatment in patients with coronary artery disease.

References

  1. Circulation. 1975 Jun;51(6):964-75 - PubMed
  2. Am J Physiol. 1982 Nov;243(5):H698-707 - PubMed
  3. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):378-83 - PubMed
  4. Am Heart J. 1981 Feb;101(2):143-9 - PubMed
  5. J Pharmacol Exp Ther. 1982 Aug;222(2):494-500 - PubMed
  6. Circulation. 1987 May;75(5):1030-6 - PubMed
  7. Ann Intern Med. 1980 Dec;93(6):875-85 - PubMed
  8. Annu Rev Pharmacol Toxicol. 1977;17:149-66 - PubMed
  9. Circ Res. 1980 Feb;46(2):190-200 - PubMed
  10. Chest. 1980 Jul;78(1 Suppl):200-4 - PubMed
  11. Am J Cardiol. 1977 Mar;39(3):396-402 - PubMed
  12. Circulation. 1987 Feb;75(2):482-90 - PubMed
  13. Am J Cardiol. 1982 Feb 18;49(3):507-10 - PubMed
  14. Am J Cardiol. 1982 Feb 1;49(2):425-30 - PubMed
  15. Am J Physiol. 1985 Mar;248(3 Pt 2):H403-11 - PubMed
  16. Am J Cardiol. 1986 Feb 1;57(4):195-8 - PubMed
  17. N Engl J Med. 1978 Dec 7;299(23 ):1271-7 - PubMed
  18. Circulation. 1986 Mar;73(3):596-605 - PubMed
  19. Am J Cardiol. 1982 Feb 18;49(3):560-6 - PubMed
  20. Chest. 1980 Jul;78(1 Suppl):205-9 - PubMed
  21. Acta Pharmacol Toxicol (Copenh). 1975 Nov;37(5):369-76 - PubMed
  22. Am Heart J. 1981 Jun;101(6):707-12 - PubMed
  23. Am J Cardiol. 1981 Jan;47(1):163-73 - PubMed
  24. Am J Cardiol. 1982 Feb 18;49(3):573-7 - PubMed
  25. Jpn Heart J. 1977 Jan;18(1):92-101 - PubMed
  26. Am J Physiol. 1985 Sep;249(3 Pt 2):H638-47 - PubMed
  27. Am Heart J. 1981 Jun;101(6):713-8 - PubMed
  28. Circulation. 1987 Jun;75(6 Pt 2):V122-7 - PubMed
  29. Am J Cardiovasc Pathol. 1987 Jan;1(1):79-90 - PubMed
  30. Circ Res. 1987 May;60(5):738-46 - PubMed
  31. Circulation. 1985 Feb;71(2):370-7 - PubMed
  32. Circulation. 1982 Jan;65(1):49-53 - PubMed
  33. Circulation. 1974 Sep;50(3):534-9 - PubMed
  34. Circulation. 1987 Jun;75(6 Pt 2):V114-21 - PubMed
  35. Am J Cardiol. 1986 Jul 1;58(1):25-30 - PubMed
  36. Circ Res. 1976 Sep;39(3):371-7 - PubMed
  37. Circulation. 1984 Jun;69(6):1171-6 - PubMed
  38. Am J Cardiol. 1982 Feb 18;49(3):567-72 - PubMed
  39. Br Med J. 1968 Jul 27;3(5612):224-7 - PubMed
  40. Circ Res. 1982 May;50(5):678-87 - PubMed
  41. Circulation. 1984 Apr;69(4):801-14 - PubMed
  42. Am J Physiol. 1984 Jul;247(1 Pt 2):H52-60 - PubMed
  43. Prog Cardiovasc Dis. 1977 Jul-Aug;20(1):55-79 - PubMed
  44. Am J Cardiol. 1979 Aug;44(2):318-24 - PubMed
  45. J Am Coll Cardiol. 1986 May;7(5):1036-46 - PubMed
  46. Eur J Cardiol. 1975 Apr;2(4):443-52 - PubMed
  47. J Pharmacol Exp Ther. 1984 Jan;228(1):28-32 - PubMed
  48. Eur J Cardiol. 1978 Aug;8(1):9-18 - PubMed
  49. Am J Cardiol. 1982 Jan;49(1):125-32 - PubMed
  50. Am J Physiol. 1981 Oct;241(4):H519-24 - PubMed
  51. Am J Cardiol. 1976 Dec;38(7):870-9 - PubMed
  52. Circulation. 1985 Jul;72(1):233-43 - PubMed
  53. Acta Med Scand. 1978;204(3):179-84 - PubMed
  54. Cardiovasc Res. 1976 Nov;10(6):623-32 - PubMed
  55. Am J Cardiol. 1981 Jan;47(1):95-101 - PubMed
  56. Circulation. 1979 May;59(5):955-68 - PubMed
  57. Am J Physiol. 1982 Feb;242(2):H240-4 - PubMed
  58. Am J Cardiol. 1980 Dec 1;46(6):1019-26 - PubMed

Substances

MeSH terms

Publication Types

Grant support